Conjunctival Melanoma With a Positive Sentinel Lymph Node

Esmaeli, Bita; Reifler, David M.; Prieto, Víctor G.; Ahmadi, M. Amir; Hidaji, Lillie; Delpassand, Ebrahim S.; Ross, M. I.

doi:10.1001/archopht.121.12.1779

Cited by 31 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a growing body of evidence demonstrating similarities in patterns of metastasis between these two entities. For cutaneous melanoma, tumor thickness appears to be the best predictor of lymph node involvement [130], with sentinel lymph node biopsy detecting nodal metastases to a greater extent than through clinical examination in cutaneous melanoma tumors of intermediate thickness (1.2 to 3.5 mm) [131–135] or significant thickness (>3.5 mm) [134,135]. Subsequent lymphadenectomy in those patients has demonstrated benefits of prolonged distant disease-free survival and overall survival in comparison to the respective cohort of melanoma patients found to be node-positive on clinical examination a median of 19.2 months after excision of the melanoma [134,135].…”

Section: Nonexcisional Adjuvant Therapymentioning

confidence: 99%

Management of conjunctival malignant melanoma: a review and update

Wong

Nanji

Karp

2014

Expert Review of Ophthalmology

136

149

View full text Add to dashboard Cite

Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, presentation, diagnosis, management, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.

show abstract

Section: Nonexcisional Adjuvant Therapymentioning

confidence: 99%

Management of conjunctival malignant melanoma: a review and update

Wong

Nanji

Karp

2014

Expert Review of Ophthalmology

136

149

View full text Add to dashboard Cite

show abstract

“…30,31,47 It has been proposed that excision of the sentinel lymph nodes allows for better staging and possibly early detection of micrometastases to the regional lymph nodes, as has been demonstrated in patients with cutaneous melanoma. [48][49][50] With documented neoplastic spread to the regional lymph nodes, resection of all of the lymph nodes in the ipsilateral head and neck is indicated. 2,8 Patients with initial lymph node metastases have a better prognosis than those presenting initially with systemic metastases.…”

Section: Managementmentioning

confidence: 99%

Malignant Melanoma of the Conjunctiva

Brownstein

2004

Cancer Control

View full text Add to dashboard Cite

Conjunctival melanoma is a relatively rare condition, occurring only 1/40th as often as choroidal melanoma and approximately 500 times less often than cutaneous melanoma. Its incidence is 0.2 to 0.8 per million in white populations. [1][2][3][4] Conjunctival melanoma is a potentially lethal neoplasm, with an average 10-year mortality rate of 30%. 1 It is identified most frequently in the perilimbal interpalpebral bulbar conjunctiva with tumors located in the palpebral or fornical conjunctiva or caruncle, plica semilunaris or eyelid margins having a worse prognosis for survival. 1,5 Conjunctival melanoma has no sexual predilection, and it is found predominately in middle-aged Malignant Melanoma of the Conjunctiva

show abstract

“…In our opinion, a SLN biopsy is indicated in the presence of ≥2 high-risk clinical and/or pathological features for nodal metastasis. Those include: (1) clinical features: tumor thickness >2 mm and nonlimbal location [16,19,20,35], and (2) pathological features: ulceration and presence of >1 mitotic figure [36,37]. …”

Section: Discussionmentioning

confidence: 99%

“…Once overt, systemic metastasis occurs and the prognosis is poor [12]. Sentinel lymph node (SLN) biopsy for staging and prognostication of the disease is only done in a few centers around the world [13,14,15,16,17,18,19,20,21,22]. Its impact on long-term survival is not known.…”

Section: Introductionmentioning

confidence: 99%

Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy

Aziz¹,

Gastman²,

Singh³

2015

Ocul Oncol Pathol

View full text Add to dashboard Cite

Conjunctival melanoma (CoM) is a rare and aggressive form of melanoma. There is a lack of consensus on a unified management plan for this disease. Recently, a few centers have adopted the regional sentinel lymph node biopsy into the staging process of CoM. This study presents a critical assessment of the role of sentinel lymph node biopsy in CoM and presents a simplified management algorithm based on high-risk clinical and pathological features.

show abstract

Conjunctival Melanoma With a Positive Sentinel Lymph Node

Cited by 31 publications

References 24 publications

Management of conjunctival malignant melanoma: a review and update

Management of conjunctival malignant melanoma: a review and update

Malignant Melanoma of the Conjunctiva

Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy

Contact Info

Product

Resources

About